The lingering mysteries of metastatic recurrence in breast cancer
Source : https://www.nature.com/articles/s41416-020-01161-4
Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a...
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis
Source : https://doi.org/10.1080/14737140.2021.1852934
ABSTRACT Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib,...
Abemaciclib in high risk early breast cancer | OncologyPRO
Abstract 2MO Over 90% of patients with breast cancer are diagnosed with early breast cancer (EBC). While many patients with HR+ disease will not recur or have distant relapse with...
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679030/
Overexpression of the HER2 receptor occurs in approximately 20% of breast cancer patients. HER2 positivity is associated with poor prognosis and aggressive tumour phenotypes, which led to rapid progress in...